Identification of urine protein biomarkers with the potential for early detection of lung cancer

Scientific Reports

Volumn 5, Issue 1, 2015, Pages

  Zhang, Hongjuan ^a,b   Cao, Jing ^c   Li, Lin ^b   Liu, Yanbin ^b   Zhao, Hong ^b   Li, Nan ^c   Li, Bo ^c   Zhang, Aiqun ^d   Huang, Huanwei ^b   Chen, She ^b   Dong, Mengqiu ^b   Yu, Lei ^e   Zhang, Jian ^c   Chen, Liang ^b  

^a TSINGHUA UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

A1BG PROTEIN, HUMAN; GLYCOPROTEIN; IMMUNOGLOBULIN; KRAS2 PROTEIN, MOUSE; LRG1 PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ANIMAL; DRUG SCREENING; EARLY CANCER DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LUNG TUMOR; MOUSE; PROTEOMICS; TUMOR CELL LINE; URINE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; LUNG NEOPLASMS; MICE; PROTEOMICS; PROTO-ONCOGENE PROTEINS P21(RAS); XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018221805     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/SREP11805     Document Type: Article

References (36)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. Journal international du cancer 127, 2893–2917 (2010).
2. Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69–90 (2011).
3. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: a cancer journal for clinicians 63, 11–30 (2013).
4. Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine 365, 395–409 (2011).
5. Henschke, C. I. et al. Survival of patients with stage I lung cancer detected on CT screening. The New England journal of medicine 355, 1763–1771 (2006).
6. Brenner, D. J. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 231, 440–445 (2004).
7. Zhang, B. H., Yang, B. H. & Tang, Z. Y. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of cancer research and clinical oncology 130, 417–422 (2004).
8. McMahon, B. J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32, 842–846 (2000).
9. Boyle, P. et al. Clinical validation of an autoantibody test for lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22, 383–389 (2011).
10. Li, R. et al. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res 13, 482–487 (2007).
11. Zhang, L. et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cellular and molecular life sciences: CMLS 69, 3341–3350 (2012).
12. Spira, A. et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nature medicine 13, 361–366 (2007).
13. Zhang, D. et al. Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer 73, 379–380 (2011).
14. Husi, H., Fearon, K. C. & Ross, J. A. Can a simple proteomics urine test assist in the early diagnosis of early-stage cancer? Expert review of proteomics 8, 555–557 (2011).
15. Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature biotechnology 24, 971–983 (2006).
16. Pitteri, S. J. et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 7, 1481–1489 (2008).
17. Taguchi, A. et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20, 289–299.
18. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674.
19. Yuan, Y. et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature biotechnology 32, 644–652 (2014).
20. Ellis, M. J. et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer discovery 3, 1108–1112 (2013).
21. Gromov, P. et al. Tumor interstitial fluid-a treasure trove of cancer biomarkers. Biochimica et biophysica acta 1834, 2259–2270 (2013).
22. Feng, Q., Yu, M. & Kiviat, N. B. Molecular biomarkers for cancer detection in blood and bodily fluids. Critical reviews in clinical laboratory sciences 43, 497–560 (2006).
23. Lee, K. D., Lee, H. S. & Jeon, C. H. Body fluid biomarkers for early detection of head and neck squamous cell carcinomas. Anticancer research 31, 1161–1167 (2011).
24. Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6, 201–205 (2009).
25. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15, 3243–3248 (2001).
26. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature medicine 14, 1351–1356 (2008).
27. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15, 3249–3262 (2001).
28. Liu, Y. et al. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PloS one 7, e51748 (2012).
29. Knekt, P. et al. Serum ceruloplasmin and the risk of cancer in Finland. British journal of cancer 65, 292–296 (1992).
30. Chen, Y. T. et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. Journal of proteomics 75, 3529–3545 (2012).
31. Girnun, G. D. et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14, 6478–6486 (2008).
32. Mathe, E. A. et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer research 74, 3259–3270 (2014).
33. Duche, J. C. et al. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clinical biochemistry 33, 197–202 (2000).
34. Fan, C., Stendahl, U., Stjernberg, N. & Beckman, L. Association between orosomucoid types and cancer. Oncology 52, 498–500 (1995).
35. Ji, H. et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25, 2105–2112 (2006).
36. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655.